Nektar Therapeutics buy HC Wainwright
Summary
This prediction is currently being closed. Massive losses of -39.01% have been the result for the BUY prediction by HC_Wainwright. HC_Wainwright has a follow-up prediction for Nektar Therapeutics where he still thinks Nektar Therapeutics is a Buy. HC_Wainwright has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by HC_Wainwright for this prediction
In the thread Discuss Nektar Therapeutics
In the thread Trading Nektar Therapeutics
Current prediction by HC_Wainwright for Nektar Therapeutics
Nektar Therapeutics
13.01.25
13.01.26
06.06.25
Stopped prediction by HC_Wainwright for Nektar Therapeutics
Nektar Therapeutics
13.03.25
13.03.26
06.06.25
Nektar Therapeutics
25.02.25
25.02.26
06.06.25

